Matthieu Coutet
Managing Partner @ AdBio partners
Paris, France
Matthieu Coutet is a seed investor at AdBio partners in Paris focused on Biotechnology and Health Care. Matthieu Coutet is based out of Paris, Ile-de-France, and is a Board Member of Signadori Bio and also served as a Partner of Sofinnova Partners. Matthieu previously worked at Integra Therapeutics as a Board Member. Matthieu Coutet attended ESIEE Paris.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries Matthieu Coutet invests in
Stages Matthieu Coutet invests in
Countries Matthieu Coutet invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (38%)
- Health Care 2 (25%)
- Genetics 1 (13%)
- Life Science 1 (13%)
- Therapeutics 1 (13%)
Stage
- Seed 3 (38%)
- Series A 1 (13%)
- Series B 1 (13%)
- Series C 1 (13%)
- Funding Round 1 (13%)
Country
- Spain 1 (13%)
- France 1 (13%)
- Belgium 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Signadori Bio is the next-generation cellular immunotherapy for cancer cure.This has culminated in the creation of a groundbreaking biotech venture in the cell and gene space that is set to advance innovative approaches in oncology. | $13M / Seed / May 06, 2026 | ||
| Signadori Bio is the next-generation cellular immunotherapy for cancer cure.This has culminated in the creation of a groundbreaking biotech venture in the cell and gene space that is set to advance innovative approaches in oncology. | Seed / Mar 18, 2025 | ||
| AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases. | $100.8M / Series C / Oct 11, 2023 | ||
| Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases. | $5.1M / Seed / Dec 02, 2021 | ||
| AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases. | $74M / Series B / Mar 10, 2021 | ||
| DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). The company, which also has research labs in Nice, France, aims to discover and develop a candidate molecule that regenerates pancreatic insulin-producing cells in patientswith diabetes, offering benefits in terms of quality of life and survival. It was discovered in the laboratory of Dr. Patrick Collombat (Inserm, CNRS, Nice University) in France, DiogenX is developing an innovative therapy with the potential to be the first beta-cell regeneration drug for diabetes. | $5.1M / Seed / Jun 16, 2020 | ||
| AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases. | $23.6M / Series A / Apr 03, 2019 | ||
| See all 8 investments → | |||
Co-Investors
About AdBio partners
AdBio partners is a European Life Sciences Venture Capital firm dedicated to seeding healthcare’s step forward.We work with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and driveinventive Life Sciences start-ups to success.We embrace European Life Sciences’ dynamic of innovation. Europe harbors a vibrant environment for medical and scientific investigation, with some of the most leading-edge academic and research centers. AdBio partners seizes the opportunity to highlight their undervalued research programs and assets and participate in structuring Europe’s biotechnology ecosystem.
AdBio partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alain Huriez
President & General Partner
|
|||
Arnaud Foussat
Operating Partner
|
|||
|
Matthieu Coutet
Managing Partner
|
|||
Francesc Dosrius
Junior Analyst
|
|||
Jeremie Mariau
Operating Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Matthieu Coutet invest in?
Matthieu Coutet invests primarily in Biotechnology, Health Care and Genetics startups, most often at Seed and Series A stage. Most of the 8 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Matthieu Coutet?
Public channels for Matthieu Coutet include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Matthieu Coutet last invest?
The most recent investment recorded for Matthieu Coutet closed in May 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
